熱景生物(688068.SH):擬出資5000萬元參設投資基金 投向早期醫療健康行業企業/項目
格隆匯1月21日丨熱景生物(688068.SH)公佈,為配合公司在醫療健康等領域的戰略業務佈局,增強產業協同的效應,探索和發現新的業務增長點,提升公司的持續競爭能力,公司擬使用自有資金與珠海惠每康新企業管理諮詢合夥企業(有限合夥)及其他有限合夥人出資發起設立長沙惠每創業投資合夥企業(有限合夥)(合夥企業最終名稱以工商核准登記為準),重點投資具有良好發展前景的早期醫療健康行業企業/項目。
該次擬投資設立的基金目標募集規模上限人民幣15億元,首輪募集資金擬認繳總額人民幣7.1億元,公司擬以自有資金認繳出資人民幣5000萬元,出資比例約7.04%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.